ArticleLe infezioni in medicina2025
Back to normality? Respiratory viruses, Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Bordetella pertussis trends: local epidemiological update after the COVID-19 storm.
Article in Le infezioni in medicina, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Article
- Epidemiological characteristics of Mycoplasma pneumoniae in hospitalized children before during and after the COVID-19 pandemic in xi'an China.Scientific reports · 2026Article
- A contemporary overview of severe community-acquired bacterial infections in pediatric intensive care units.Annals of intensive care · 2026Article
- Enterovirus respiratory infection in adults: an overlooked clinical burden emerging in the post-pandemic era.Le infezioni in medicina · 2026Article
- Clinical characteristics of community acquired pneumonia due toLe infezioni in medicina · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The COVID-19 pandemic deeply impacted the epidemiology of respiratory viruses and bacteria, including Methods: The study was conducted in the five hospitals of the Friuli Venezia Giulia region, in northeastern Italy from January 2021 to December 2024. A total of 11,208 respiratory samples from adult and pediatric patients displaying symptoms of ARIs, but negative for SARS-CoV-2, in accordance with our testing protocols, were tested for the following pathogens: influenza A and B (FLU A-B), adenovirus (ADV), coronaviruses (COV) 229E, NL63, OC43, bocavirus (BOV), enterovirus (EV), metapneumovirus (MPV), rhinovirus (RV), parainfluenza types 1-4 (PIV 1-4), respiratory syncytial virus A and B (RSV A/B), MP, CP, BP, and Results: The number of tests increased from 1,076 in 2021 to 4,377 in 2024. Overall positivity rates rose as follows: 27.4% (295/1,076) in 2021, 33.6% (714/2,125) in 2022, 41.3% (1,500/3,631) in 2023, and 47.2% (2,067/4,377) in 2024. RV, ADV, BOV, COV, PIV 1-4, MPV, and RSV A/B gradually returned to pre-pandemic circulation levels. FLU A-B, not detected in 2021, re-emerged in 2022. MP, BP, and CP, nearly absent in 2021 and 2022, reappeared in 2023. Conclusion: This retrospective study assessed the circulation of respiratory viruses, MP, CP and BP in our geographical area, observing their gradual and asynchronous re-emergence following the COVID-19 pandemic. Strengthening advanced molecular microbiological diagnostics within clinical and epidemiological settings is crucial for supporting new surveillance models and promoting the judicious use of antibiotics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.